Protagonist Therapeutics shows strong revenue growth of 99% year over year and a positive chart setup including a golden cross and bullish MACD, but pipeline concentration in only two assets (Icotyde and rusfertide) combined with a single partnership counterparty creates binary risk that overwhelms the bullish technical picture.
Thesis pillars
- Revenue Growth Trajectory→Stable
- Pipeline Concentration Binary Risk↑Improving
- Golden Cross Momentum→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 25, 2026
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis
Healthcare · Biotechnology
Wait for pullback to $135.82. At $142.14 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $135.82 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Pipeline: Icotyde and rusfertide; Concentration risk — Counterparty: JNJ.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with two NDA-stage programs: Icotyde (oral IL-23R antagonist licensed to Johnson & Johnson, FDA NDA filed July 2025 for psoriasis) and rusfertide (injectable hepcidin mimetic partnered with Takeda, FDA NDA... Read more
Wait for pullback to $135.82. At $142.14 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $135.82 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Pipeline: Icotyde and rusfertide; Concentration risk — Counterparty: JNJ. Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. Score 5.6/10, moderate confidence.
Passes 5/8 gates (positive momentum, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: speculative.
About Protagonist Therapeutics, Inc.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics had two programs at the NDA stage at fiscal year-end 2025: Icotyde, an oral IL-23R antagonist licensed to Johnson & Johnson, for which JNJ filed an FDA NDA in July 2025 for moderate-to-severe plaque psoriasis and submitted an application to the EMA in September 2025; and rusfertide, an injectable hepcidin mimetic, for which Takeda submitted an FDA NDA in December 2025 for polycythemia vera after rusfertide received Breakthrough Therapy designation in August 2025. The company held approximately $646.0 million in cash, cash equivalents, and marketable securities at December 31, 2025 and has never generated product sales revenue.
Protagonist Therapeutics earns revenue from collaboration milestone payments and, upon product approval, tiered royalties. Under the JNJ License and Collaboration Agreement entered in July 2017 and last amended in November 2024, JNJ assumed responsibility for all clinical development beyond Phase 1 and for commercialization; Protagonist has earned $337.5 million in milestone payments from JNJ to date and is eligible for up to $630 million in future milestones, plus tiered royalties of 6% to 10% on worldwide net Icotyde sales (weighted average 7.25% on the first $4.0 billion in annual net sales). Under the Takeda Collaboration Agreement signed in January 2024, Protagonist received a $300 million upfront payment and a $25 million milestone in September 2025 upon completion of the Phase 3 VERIFY trial, with up to $975 million in additional milestones available. The company expects to exercise its opt-out right from US profit-and-loss sharing in Q2 2026, converting to royalties of 14% to 29% on worldwide net rusfertide sales.
Show full overview
Both NDA-stage programs carry regulatory binary risk at the FDA. The agency could refuse applications, request additional data, or issue Complete Response Letters; in September 2021, rusfertide clinical studies were placed on a brief full clinical hold following a non-clinical finding of benign and malignant subcutaneous skin tumors in a rasH2 transgenic mouse model. JNJ has disclosed it expects to launch Icotyde in the United States in 2026, subject to regulatory approval, while Takeda expects to launch rusfertide in the second half of 2026, subject to approval. If either NDA fails, the royalty stream that constitutes the primary source of non-milestone income would not materialize on the anticipated timeline.
See also: Healthcare · Biotechnology
From Protagonist Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Protagonist Therapeutics, Inc.
Latest news
- NEWS Protagonist Therapeutics (PTGX) Insider Trading Activity 2026 - MarketBeat — MarketBeat neutral
- NEWS Protagonist Therapeutics (PTGX) Insider Trading Activity 2026 - marketbeat.com — marketbeat.com neutral
- NEWS Why Did Protagonist Therapeutics Stock Soar Today? - MSN — MSN positive
- NEWS Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Zack — Zacks Investment Research positive
Generated 2026-10-29T12:43:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineIcotyde and rusfertide10-K Item 1A: 'Our future success is substantially dependent on our ability and the ability of our collaborators...such as Icotyde and rusfertide'
- HIGHcounterpartyJNJ10-K Item 1A: 'If JNJ does not elect to continue the development of or successfully commercialize Icotyde...our business and business prospects would be adversely affected'
- HIGHcounterpartyTakeda10-K Item 1A: 'Under the terms of the Takeda Collaboration Agreement, Takeda may terminate the agreement for convenience in its entirety or as to a major region'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $135.82. At $142.14 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $135.82 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Pipeline: Icotyde and rusfertide; Concentration risk — Counterparty: JNJ. Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. Target $155.36 (+9.3%), stop $126.31 (−12.5%), A.R:R 0.8:1. Score 5.6/10, moderate confidence.
Take-profit target: $155.36 (+9.3% upside). Target $155.36 (+9.3%), stop $126.31 (−12.5%), A.R:R 0.8:1. Stop-loss: $126.31.
Concentration risk — Pipeline: Icotyde and rusfertide; Concentration risk — Counterparty: JNJ; Thin upside margin: 9.3%.
Protagonist Therapeutics, Inc. trades at a P/E of 138.0 (forward -1432.0). TrendMatrix value score: 3.6/10. Verdict: Buy (Wait for Entry).
20 analysts cover PTGX with a consensus score of 4.3/5. Average price target: $179.
What does Protagonist Therapeutics, Inc. do?Protagonist Therapeutics is a clinical-stage biopharmaceutical company with two NDA-stage programs: Icotyde (oral...
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with two NDA-stage programs: Icotyde (oral IL-23R antagonist licensed to Johnson & Johnson, FDA NDA filed July 2025 for psoriasis) and rusfertide (injectable hepcidin mimetic partnered with Takeda, FDA NDA filed December 2025 for polycythemia vera). Milestone and royalty payments from JNJ and Takeda are the sole revenue sources; the company held $646 million in cash at December 31, 2025.